Payment overview · 2025
General Payments
$1,240.73
63 reported records · 16 companies
Healthcare provider profile · identity verified
Kenneth Douglas Shank, DO
Allopathic & Osteopathic Physicians|Family Medicine · ALBEMARLE, NC · NPI 1083695159
Verified facts
What the public records show
CMS Open Payments records show Kenneth Douglas Shank, DO received $1,240.73 in general payments during 2025 across 63 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Paxlovid, Rybelsus, Shingrix, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 317 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 317 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $275.61 | 22.2% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $197.68 | 15.9% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $170.01 | 13.7% | 10 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $119.70 | 9.7% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $89.66 | 7.2% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $81.22 | 6.5% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $60.10 | 4.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $50.54 | 4.1% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $39.59 | 3.2% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $37.55 | 3.0% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.29 | 2.4% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $22.06 | 1.8% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $19.96 | 1.6% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.75 | 1.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.31 | 1.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $13.70 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,240.73 | 63 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $219.23 | 7 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $119.70 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $114.72 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $89.66 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $86.31 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $86.31 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $80.09 | 5 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $64.29 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $55.29 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $55.29 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $55.29 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $51.38 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $40.13 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $37.55 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.65 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.65 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $32.52 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $32.18 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.29 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $24.20 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $24.19 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22.06 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.97 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $17.75 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 29 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 317 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 97 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 125 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 26 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 142 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 94 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 19 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 44 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
105 | 24 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
97 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
125 | 29 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
317 | 58 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
44 | 42 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
125 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
142 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
145 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
94 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
29 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
317 | 58 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 742 | 216 |
| Levothyroxine Sodium | Levothyroxine Sodium | 647 | 155 |
| Atorvastatin Calcium | Atorvastatin Calcium | 641 | 178 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 566 | 96 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 527 | 150 |
| Pantoprazole Sodium | Pantoprazole Sodium | 489 | 145 |
| Omeprazole | Omeprazole | 470 | 134 |
| Lisinopril | Lisinopril | 452 | 121 |
| Gabapentin | Gabapentin | 333 | 96 |
| Metoprolol Succinate | Metoprolol Succinate | 332 | 101 |
| Eliquis | Apixaban | 317 | 58 |
| Irbesartan | Irbesartan | 280 | 78 |
| Metformin Hcl | Metformin Hcl | 280 | 81 |
| Potassium Chloride | Potassium Chloride | 270 | 77 |
| Allopurinol | Allopurinol | 266 | 72 |
| Furosemide | Furosemide | 253 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 246 | 65 |
| Clonazepam | Clonazepam | 242 | 40 |
| Montelukast Sodium | Montelukast Sodium | 242 | 65 |
| Trazodone Hcl | Trazodone Hcl | 240 | 73 |
| Fluticasone Propionate | Fluticasone Propionate | 224 | 90 |
| Escitalopram Oxalate | Escitalopram Oxalate | 222 | 61 |
| Carvedilol | Carvedilol | 218 | 64 |
| Clopidogrel | Clopidogrel Bisulfate | 207 | 61 |
| Losartan Potassium | Losartan Potassium | 204 | 61 |
| Simvastatin | Simvastatin | 203 | 60 |
| Lorazepam | Lorazepam | 201 | 36 |
| Alprazolam | Alprazolam | 199 | 35 |
| Tramadol Hcl | Tramadol Hcl | 199 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 197 | 61 |
| Sertraline Hcl | Sertraline Hcl | 190 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 177 | 82 |
| Meloxicam | Meloxicam | 177 | 56 |
| Pravastatin Sodium | Pravastatin Sodium | 173 | 45 |
| Pregabalin | Pregabalin | 167 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 164 | 45 |
| Donepezil Hcl | Donepezil Hcl | 149 | 45 |
| Trulicity | Dulaglutide | 145 | 24 |
| Mounjaro | Tirzepatide | 142 | 19 |
| Finasteride | Finasteride | 140 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 139 | 38 |
| Oxycodone Hcl | Oxycodone Hcl | 139 | 16 |
| Bupropion Xl | Bupropion Hcl | 136 | 39 |
| Prednisone | Prednisone | 135 | 94 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 134 | 36 |
| Glimepiride | Glimepiride | 127 | 34 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 127 | 59 |
| Jardiance | Empagliflozin | 125 | 29 |
| Warfarin Sodium | Warfarin Sodium | 124 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 121 | 34 |
| Diazepam | Diazepam | 120 | 24 |
| Ezetimibe | Ezetimibe | 120 | 37 |
| Quetiapine Fumarate | Quetiapine Fumarate | 119 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 117 | 35 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 114 | 25 |
| Azithromycin | Azithromycin | 113 | 62 |
| Buspirone Hcl | Buspirone Hcl | 107 | 31 |
| Synthroid | Levothyroxine Sodium | 105 | 24 |
| Alendronate Sodium | Alendronate Sodium | 102 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 98 | 26 |
| Lovastatin | Lovastatin | 98 | 28 |
| Farxiga | Dapagliflozin Propanediol | 97 | 27 |
| Celecoxib | Celecoxib | 94 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 94 | 28 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 94 | 27 |
| Ozempic | Semaglutide | 94 | 22 |
| Cephalexin | Cephalexin | 86 | 65 |
| Propranolol Hcl | Propranolol Hcl | 85 | 22 |
| Fenofibrate | Fenofibrate | 77 | 21 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 76 | 76 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 76 | 27 |
| Spironolactone | Spironolactone | 75 | 22 |
| Mirtazapine | Mirtazapine | 74 | 22 |
| Metformin Hcl Er | Metformin Hcl | 73 | 27 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 68 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 65 | 52 |
| Methocarbamol | Methocarbamol | 65 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 64 | 20 |
| Famotidine | Famotidine | 62 | 19 |
| Morphine Sulfate Er | Morphine Sulfate | 62 | suppressed |
| Amoxicillin | Amoxicillin | 61 | 52 |
| Methylprednisolone | Methylprednisolone | 61 | 55 |
| Torsemide | Torsemide | 61 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 59 | 49 |
| Ketoconazole | Ketoconazole | 57 | 34 |
| Tresiba Flextouch U-100 | Insulin Degludec | 55 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 14 |
| Azelastine Hcl | Azelastine Hcl | 52 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | 18 |
| Meclizine Hcl | Meclizine Hcl | 49 | 23 |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Atenolol | Atenolol | 47 | 12 |
| Estradiol | Estradiol | 47 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 47 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 47 | 29 |
| Telmisartan | Telmisartan | 47 | 13 |
| Valsartan | Valsartan | 46 | 12 |
| Glipizide | Glipizide | 45 | 15 |
| Nitroglycerin | Nitroglycerin | 45 | 24 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 44 | 42 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | 15 |
| Ondansetron Odt | Ondansetron | 43 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 41 | 13 |
| Droplet Pen Needle | Pen Needle, Diabetic | 39 | 12 |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 39 | 13 |
| Aripiprazole | Aripiprazole | 38 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 37 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 35 | suppressed |
| Ibuprofen | Ibuprofen | 35 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 35 | 11 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 34 | suppressed |
| Fluconazole | Fluconazole | 34 | 25 |
| Repaglinide | Repaglinide | 34 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 33 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 25 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Repatha Sureclick | Evolocumab | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | 13 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 29 | 29 |
| Dexamethasone | Dexamethasone | 29 | 27 |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Felodipine Er | Felodipine | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | 18 |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 28 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | 12 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 26 | suppressed |
| Linzess | Linaclotide | 26 | 12 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 25 | 11 |
| Valacyclovir | Valacyclovir Hcl | 25 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 23 | suppressed |
| Klor-Con M20 | Potassium Chloride | 23 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Nucynta | Tapentadol Hcl | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | 11 |
| Glipizide Er | Glipizide | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Trospium Chloride | Trospium Chloride | 21 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 17 |
| Temazepam | Temazepam | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 12 |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Indomethacin | Indomethacin | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Haloperidol | Haloperidol | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Ssd | Silver Sulfadiazine | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,240.73 · 63 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, ACCRUFER, AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, Fluad, Flucelvax, JARDIANCE, Kerendia, LINZESS, Leqembi, MOUNJARO, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VRAYLAR, Wegovy, ZAVZPRET | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error